About Site
Affordable Medicines Facility - malaria
Board
Business Opportunities
Country Coordinating Mechanisms
Civil Society and the Private Sector
Donate
Donors
Employment
Friends of the Fund
Global Fund Transformation
High Level Independent Review Panel
Innovative Financing
Local Fund Agents
Monitoring and Evaluation
National Strategy Applications
Office of Inspector General
Partnership Forum
Performance Based Funding
Private Sector
Pharmaceutical Procurement and Supply Management
Regional Meetings
Saving Lives: Stories from the Fight
Technical Evaluation and Reference Group
Technical Review Panel
Transitional Funding Mechanism
Summary:
The Global Fund has made an explicit commitment to making an impact on the three diseases. The overall objective of Study Area 3 - the Health Impact Evaluation - is to comprehensively assess, in selected countries, the collective impact that the Global Fund and other international and national partners have achieved on reducing the disease burden of AIDS, TB and malaria. The study focuses on these national disease control programs in 18 countries and seeks to assess overall progress toward the Millennium Development Goals. The Health Impact Evaluation demonstrates that the rapid increase in funding from all partners has resulted in a major expansion in access to services in these countries and improved coverage of interventions. While the study reveals important improvements, it also highlights the urgent need to strengthen health systems to accelerate scale-up.
Background:
The Five-Year Evaluation is an independent, Board-mandated evaluation being conducted under the oversight of the Technical Evaluation Reference Group (TERG). Study Area 1 of the Five-Year Evaluation was completed in November 2007 and examined the organizational efficiency and effectiveness of the Global Fund, its progress to date and critical areas for improvement. The study of the Global Fund’s partner environment in 16 countries and at the global level (Study Area 2) was presented to the Board in November 2008. Study Area 3 is the most extensive component of the Five-Year Evaluation, and involved the examination of impact on the three diseases in 18 countries. Both the Study Area 3 report and the final Five-Year Evaluation Synthesis Report, which synthesizes the findings and recommendations from all three study areas, were presented to the Global Fund Board at its Nineteenth Board Meeting in May 2009.